CD44 and breast cancer: Figure 5c and 5d shows evidence that ICON was equally effective in killing CSCs and non-CSC breast cancer cells, using either CD24 CD44 antibodies-based protocol (R&D) (Figure 5c) or CD133 antibody-based protocol (StemCell) (Figure 5d).